Cargando…

Personalized Approach to Severe Asthma

Detalles Bibliográficos
Autores principales:	Heffler, Enrico, Canonica, Giorgio Walter, Diamant, Zuzana, Fonseca, Joao, Malinovschi, Andrei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323523/ https://www.ncbi.nlm.nih.gov/pubmed/30671448 http://dx.doi.org/10.1155/2018/2465172

Ejemplares similares

Interleukin-5 in the Pathophysiology of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2019)

Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis
por: Heffler, Enrico, et al.
Publicado: (2020)

Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey
por: Crimi, Claudia, et al.
Publicado: (2023)

Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI
por: Senna, Gianenrico, et al.
Publicado: (2020)

Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry
por: Puggioni, Francesca, et al.
Publicado: (2020)

Biologics in severe asthma: the role of real-world evidence from registries
por: Paoletti, Giovanni, et al.
Publicado: (2022)

Application of nitric oxide measurements in clinical conditions beyond asthma
por: Malinovschi, Andrei, et al.
Publicado: (2015)

The Present and Future of Allergen Immunotherapy in Personalized Medicine
por: Ridolo, Erminia, et al.
Publicado: (2022)

Biologics and airway remodeling in severe asthma
por: Varricchi, Gilda, et al.
Publicado: (2022)

Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets
por: Pelaia, Corrado, et al.
Publicado: (2022)

Choosing wisely in Allergology: a Slow Medicine approach to the discipline promoted by the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC)
por: Heffler, Enrico, et al.
Publicado: (2015)

Asthma research and practice: a new journey begins
por: Celedon, Juan C., et al.
Publicado: (2015)

A critical appraisal on AIT in childhood asthma
por: Ferrando, Matteo, et al.
Publicado: (2018)

Severe asthma: One disease and multiple definitions
por: Bagnasco, Diego, et al.
Publicado: (2021)

SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma
por: Senna, G., et al.
Publicado: (2017)

Anomalous asthma and chronic obstructive pulmonary disease Google Trends patterns during the COVID-19 pandemic
por: Sousa-Pinto, Bernardo, et al.
Publicado: (2020)

Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center
por: Solidoro, Paolo, et al.
Publicado: (2022)

Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study
por: Solidoro, Paolo, et al.
Publicado: (2019)

Critical evaluation of asthma biomarkers in clinical practice
por: Guida, Giuseppe, et al.
Publicado: (2022)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

European medicines agency guideline for biological medicinal products: a further step for a safe use of biosimilars
por: Agostini, Carlo, et al.
Publicado: (2015)

Therapeutic interventions in severe asthma
por: Canonica, Giorgio Walter, et al.
Publicado: (2016)

Inflammatory patterns in fixed airflow obstruction are dependent on the presence of asthma
por: Mogensen, Ida, et al.
Publicado: (2020)

Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry
por: Canonica, Giorgio Walter, et al.
Publicado: (2019)

Biomarkers and severe asthma: a critical appraisal
por: Chiappori, Alessandra, et al.
Publicado: (2015)

EUFOREA consensus on biologics for CRSwNP with or without asthma
por: Fokkens, Wytske J., et al.
Publicado: (2019)

Is allergic sensitization relevant in severe asthma? Which allergens may be culprit?
por: Lombardi, Carlo, et al.
Publicado: (2017)

Extended IgE profile based on an allergen macroarray: a novel tool for precision medicine in allergy diagnosis
por: Heffler, Enrico, et al.
Publicado: (2018)

Venom Immunotherapy and Aeroallergen Immunotherapy: How Do Their Outcomes Differ?
por: Incorvaia, Cristoforo, et al.
Publicado: (2022)

Patient's Adherence and Compliance and Quality of Life During/After VIT
por: Incorvaia, Cristoforo, et al.
Publicado: (2022)

Severe vitamin D deficiency is associated with frequent exacerbations and hospitalization in COPD patients
por: Malinovschi, Andrei, et al.
Publicado: (2014)

Targeted therapy in severe asthma today: focus on immunoglobulin E
por: Pelaia, Girolamo, et al.
Publicado: (2017)

Personalized Medicine in Asthma: Current Approach and Future Perspectives
por: Nolasco, Santi, et al.
Publicado: (2023)

Cutting Edge: Biomarkers for Chronic Spontaneous Urticaria
por: Folci, Marco, et al.
Publicado: (2018)

Overcoming Barriers to the Effective Management of Severe Asthma in Italy
por: Paggiaro, Pierluigi, et al.
Publicado: (2021)

Escaping the trap of allergic rhinitis
por: Rossi, Oliviero, et al.
Publicado: (2015)

Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs
por: Varricchi, Gilda, et al.
Publicado: (2016)

Having concomitant asthma phenotypes is common and independently relates to poor lung function in NHANES 2007–2012
por: Amaral, Rita, et al.
Publicado: (2018)

Comparison of hypothesis- and data-driven asthma phenotypes in NHANES 2007–2012: the importance of comprehensive data availability
por: Amaral, Rita, et al.
Publicado: (2019)

Psychological aspects in asthma: do psychological factors affect asthma management?
por: Baiardini, Ilaria, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_05r7r5rpg8ijeeqp78mhhoi5t7